Organic Active Ingredients TRIZ Cases

Cyclic glycyl proline analogs treat underlying neurological causes of autism by normalizing social behavior and reducing hyperactivity.

Non-lytic aerolysin binds GPI anchors to quantify PNH Type II cells, resolving unreliable diagnostics caused by red blood cell turnover.

Angiotensin II reduces cardiac injury by lowering troponin levels and minimizing catecholamine exposure during vasodilatory shock treatment.

Topical diene compounds inhibit UV-induced DNA damage, preventing skin cancer by preserving cell viability.

A VEGF-B inhibitor compound reduces stroke damage by blocking specific signaling pathways.

Therapeutic heterocyclic compounds block IDO1-mediated immunosuppression to improve prognosis in cancer and chronic infections.

Direct modified release coating on band-sealed gelatin capsules eliminates precoating steps.

Drying a nucleic acid and cationic lipid mixture into a solid tablet removes sterile preparation constraints while maintaining biological activity.

Antagonist antibodies block netrin-1 and UNC5B receptors to remove retained macrophages from atherosclerotic plaques, resolving chronic inflammation.

An interferon alpha-Fc conjugate extends half-life and reduces chemotherapy side effects by enabling lower gemcitabine doses.

Incorporating artificial Ds-Da nucleotides into DNA aptamers improves binding affinity and stability for cancer detection applications.

Cereblon-associated proteins predict immunomodulatory compound sensitivity in diffuse large B-cell lymphoma and multiple myeloma patients.

Optimizing crystallization conditions for chidamide crystal form A resolves impurity issues, ensuring stable bioavailability.

Pyrazolo[3,4-d]pyrimidinone compounds selectively inhibit DAPKs and PIM kinases to treat cancers lacking effective targeted therapies.

Chimeric polynucleotide formulations incorporate amino acids to enhance protein production efficiency and stability.

Combining aldosterone with NSAIDs reduces hormone dosage while maintaining therapeutic effectiveness against presbycusis.

A metal oxide nanoparticle core coated with a cationic lanthanide shell linked to a polymer and pentamidine drug molecule.

Modified small molecules reduce parasite numbers while lowering toxicity to overcome drug-resistant strains.

Esters merge retinoid and bakuchiol moieties to enhance skin health while maintaining formulation versatility.

Molecularly dispersing the ERK inhibitor in HPMCAS overcomes low solubility to enhance pharmacokinetic profiles.

Cinnamoyl-piperazine derivatives antagonize PAR-1 receptors, resolving the trade-off between antithrombotic efficacy and bleeding risk.

A PLGA copolymer matrix embeds metalloporphyrins to enable sustained intratumoral drug diffusion.

Acid-free granulation stabilizes statins and ACE inhibitors, resolving chemical incompatibility while maintaining patient compliance.

Antisense oligonucleotides induce exon skipping in SLC7A11 pre-mRNA to reduce cystine/glutamate antiporter expression and limit cancer cell proliferation.

Encapsulating decitabine in biodegradable nanogels protects the drug from degradation while enabling controlled release to overcome tumor resistance.

Radiation-inactivated blood serum eye drops replace artificial tears lacking essential tear components.

Anti-CD5 antibodies selectively deplete CD5+ immune cells, preventing graft rejection and facilitating stem cell engraftment without broad immunosuppression.

Zwitterionic chitosan derivatives shield cationic PAMAM dendrimers, suppressing immune activation and inflammatory responses during parenteral administration.

TRAP-targeting nanoparticles concentrate azeliragon at injury sites during early healing phases, reducing scar tissue formation.

Histamine H4 receptor antagonists reverse cognitive deficits by shifting microglia from harmful to beneficial states, clearing amyloid plaques.

A luminescent compound selectively inhibits cancer stem cells and enables their detection through specific chemical properties.

Combining beta-caryophyllene with antipsychotics addresses chronic negative symptoms through multi-target therapeutic efficacy.

Formula I retinoid compounds improve tumor cell inhibition rates by substituting hydrogen atoms with functional groups at specific positions.

Combining systemic curcuminoids with specific irradiance overcomes low bioavailability to achieve high PASI reduction.

SUL-138 chromanol compounds target amyloid-beta polymerization to reduce plaque load while improving memory function and synaptic connectivity.

A tadalafil powder formulation uses xanthan gum to create a stable aqueous suspension for oral administration.

Selective MK2 inhibitors address safety concerns in p38 MAPK treatment by optimizing potency through parameter changes.

Formula I compounds antagonize the mineralocorticoid receptor, addressing suboptimal therapeutic effectiveness in hypertension and heart failure.

An anti-ITGA6/B4 antibody blocks cancer cell adhesion to bone marrow niches.

A liposomal topical formulation delivers finasteride into the scalp via a hydrogel matrix, reducing systemic side effects from oral administration.

Dupilumab blocks Th2 inflammation to lower nasal polyp volume and improve airflow without the recurrence rates of corticosteroid therapy.

Terminally activated monofunctional polyoxazoline derivatives enable stable conjugation to target molecules under diverse reaction conditions.

A bicyclic pyridine compound inhibits placental leucine aminopeptidase to preserve endogenous arginine-vasopressin levels.

Optimized dosing schedules for anti-Trop-2 antibody-drug conjugates deliver targeted therapeutic efficacy.

Pyrazolopyridinone compounds overcome resistance from gatekeeper mutations in FGFRs, maintaining therapeutic efficacy against altered signaling pathways.

Targeting EGFR signaling with inhibitors like cetuximab reduces fungal damage and prolongs survival without nephrotoxicity.

Iron crosslinks multiblock copolymer micelles to encapsulate insoluble SN-38, resolving solubility and toxicity trade-offs.

17-alpha hydroxyprogesterone caproate formulations mitigate proinflammatory responses and respiratory conditions associated with cytokine storms.

Substituted 2-aminopyridine derivatives inhibit ALK kinase to overcome drug resistance in non-small cell lung carcinoma.